The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")...
~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...
~ Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder ~ SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...
~ Geoff Birkett, Chief Commercial Officer, Invited to Serve on the Opening Panel at the EPHMRA 2024 Annual Conference ~ SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:EN...
PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce ...
~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)...
~ Webcast Replay Available on Ensysce's Investor Relations Website ~ SAN DIEGO, CA / ACCESSWIRE / April 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stag...
SAN DIEGO, CA / ACCESSWIRE / April 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pa...
Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / ...